Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

16. September 2020

September 2020,
by Cormac Sheridan

Download

Search for:

Adrenomed Announces Participation in Scientific and Industry Events in September and October 2021

30. August 2021

#DeutschlandErkenntSepsis

22. February 2021

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

4. January 2021

Efficacy Data from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented at DIVI

2. December 2020

Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

30. November 2020

Positive Results from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented during e-ISICEM

16. September 2020

More News

Media Coverage

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

28. July 2021

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

19. May 2021

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

29. April 2021

Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

16. September 2020

Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

28. August 2020

Article in First Word: Viewpoints – Adrenomed looking to provide a shock of its own in sepsis

19. March 2020

Recent Events

Weimar Sepsis Update, September 8 – 10, 2021

23. August 2021

ISICEM, August 31 – September 3, 2021

23. August 2021

BIO Digital, 10–18 June, 2021

7. June 2021

Bio€quity Europe, 17–19 May, 2021

19. April 2021

BIO-Europe Spring, 22-25 March, 2021

15. March 2021

Participation in Virtual J.P. Morgan 39th Annual Healthcare Conference 2021, 11 – 15 January 2021

11. December 2020

More Events

Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

Recent News

Adrenomed Announces Participation in Scientific and Industry Events in September and October 2021

#DeutschlandErkenntSepsis

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

Efficacy Data from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented at DIVI

Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

Positive Results from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented during e-ISICEM

Media Coverage

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

Article in First Word: Viewpoints – Adrenomed looking to provide a shock of its own in sepsis

Recent Events

Weimar Sepsis Update, September 8 – 10, 2021

ISICEM, August 31 – September 3, 2021

BIO Digital, 10–18 June, 2021

Bio€quity Europe, 17–19 May, 2021

BIO-Europe Spring, 22-25 March, 2021

Participation in Virtual J.P. Morgan 39th Annual Healthcare Conference 2021, 11 – 15 January 2021

Archive